Drug Profile
Research programme: carbon nanotube anticancer therapeutics - Ensysce Biosciences
Latest Information Update: 23 Feb 2023
Price :
$50
*
At a glance
- Originator Ensysce Biosciences
- Class Doxorubicins; Paclitaxels; Small interfering RNA
- Mechanism of Action DNA intercalators; Mitosis inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; RNA interference; Tubulin inhibitors; Tubulin polymerisation promoters; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 23 Feb 2023 Discontinued - Preclinical for Cancer in USA (IV) (Ensysce Biosciences pipeline, February 2023)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Cancer in USA (IV)
- 11 Jul 2015 Preclinical development is ongoing in USA